Yahoo
LSE - Delayed Quote GBp

Solvonis Therapeutics plc (SVNS.L)

0.1100 -0.0025 (-2.22%)
As of 10:43:15 AM GMT+1. Market Open.
Chart Range Bar
Loading chart for SVNS.L
  • Previous Close 0.1125
  • Open 0.1195
  • Bid 0.1050 x --
  • Ask 0.1200 x --
  • Day's Range 0.1100 - 0.1200
  • 52 Week Range 0.0950 - 0.3900
  • Volume 15,710,165
  • Avg. Volume 27,197,191
  • Market Cap (intraday) 8.69M
  • Beta (5Y Monthly) 1.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1.70

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

solvonis.com

6

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/13/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

SVNS.L
61.29%
FTSE 100 (^FTSE)
8.16%

1-Year Return

SVNS.L
66.20%
FTSE 100 (^FTSE)
13.76%

3-Year Return

SVNS.L
93.51%
FTSE 100 (^FTSE)
41.35%

5-Year Return

SVNS.L
99.46%
FTSE 100 (^FTSE)
50.41%

Analyst Insights

View More

Analyst Price Targets

1.70
1.70 Average
0.1100 Current
1.70 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    9.08M

  • Enterprise Value

    7.44M

  • Trailing P/E

    1.35

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.47

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.57%

  • Return on Equity (ttm)

    -94.61%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.56M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    659k

  • Total Debt/Equity (mrq)

    1.50%

  • Levered Free Cash Flow (ttm)

    -2.62M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: